Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalFRA:ZCY -0.74%58 ROC (Joel Greenblatt) % is 23.83% as of May. 2026, which is 74% below its 10-year median of 91.93. GuruFocus rates FRA:ZCY with a GF Score™ of 58/100 and a GF Value™ of €4.31. The stock has 4 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 70.27% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cryo-Cell International's annualized ROC (Joel Greenblatt) % for the quarter that ended in May. 2026 was 23.83%.
The historical rank and industry rank for Cryo-Cell International's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:ZCY'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -165.02 Med: 91.93 Max: 529.39
Current: -2.86
During the past 13 years, Cryo-Cell International's highest ROC (Joel Greenblatt) % was 529.39%. The lowest was -165.02%. And the median was 91.93%.
FRA:ZCY's ROC (Joel Greenblatt) % is ranked worse than 70.27% of 666
companies
in the Healthcare Providers & Services industry
Industry Median: 12.485
vs FRA:ZCY: -2.86
Cryo-Cell International's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Cryo-Cell International (FRA:ZCY) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Cryo-Cell International ROC (Joel Greenblatt) % Related Terms
Cryo-Cell International ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Cryo-Cell International's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International ROC (Joel Greenblatt) % Chart
FRA:ZCY vs EHSI, PIII, CCM: ROC (Joel Greenblatt) % Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's ROC (Joel Greenblatt) % falls into.
Cryo-Cell International ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (May. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 23.83% mean?
Cryo-Cell International (FRA:ZCY) has a ROC (Joel Greenblatt) % of 23.83% as of May. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cryo-Cell International and its competitors. This is 74% below median its historical median of 91.93. According to the industry distribution chart, Cryo-Cell International ranks #468 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 70.3%.
Is Cryo-Cell International's ROC (Joel Greenblatt) % too high?
Cryo-Cell International's current ROC (Joel Greenblatt) % of 23.83% is 74% below median its 10-year median of 91.93. The Healthcare Providers & Services industry median ROC (Joel Greenblatt) % is 12.49. Cryo-Cell International's value of 23.83% is 90.9% above this industry median. Based on the distribution chart, Cryo-Cell International ranks #468 out of 666 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cryo-Cell International has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's ROC (Joel Greenblatt) % compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #468 out of 666 companies for ROC (Joel Greenblatt) %. This places Cryo-Cell International in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 12.49. Cryo-Cell International's value of 23.83% is 90.9% above this benchmark. While the company's 10-year median is 91.93 vs. the industry median of 12.49, Cryo-Cell International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.49, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current ROC (Joel Greenblatt) % of 23.83% is 90.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current ROC (Joel Greenblatt) % is 23.83%, which is 74% below median its own 10-year median of 91.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Cryo-Cell International (FRA:ZCY) has a current ROC (Joel Greenblatt) % of 23.83%. The stock's GF Value™ is €4.31, compared to a current price of €2.70 — trading 37.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 23.83%, which is 74% below median its 10-year median of 91.93 and 90.9% above the Healthcare Providers & Services industry median of 12.49. Cryo-Cell International's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Cryo-Cell International (FRA:ZCY), the current ROC (Joel Greenblatt) % is 23.83% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (FRA:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.70 is trading 37.4% below its estimated GF Value™ of €4.31.
Key valuation signals for FRA:ZCY:
ROC (Joel Greenblatt) %: 23.83% (74% below median its 10-year median of 91.93)
GF Value™: €4.31 vs. price of €2.70 (37.4% below fair value)
Industry Position: 90.9% above the Healthcare Providers & Services median (#468 of 666)
No single metric tells the full story. See the FRA:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for FRA:ZCY
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZCY has been successfully added to your 
